| Autor: |
Lauermann JL; Department of Ophthalmology, University of Münster, Münster, Germany., Sochurek JAM; Laboratory for Angiogenesis and Ocular Cell Transplantation, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany., Plöttner P; Department of Neurology, University of Lübeck, Lübeck, Germany., Alten F; Department of Ophthalmology, University of Münster, Münster, Germany., Kasten M; Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.; Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck, Germany., Prasuhn J; Department of Neurology, University of Lübeck, Lübeck, Germany.; Institute of Neurogenetics, University of Lübeck, Lübeck, Germany., Brüggemann N; Department of Neurology, University of Lübeck, Lübeck, Germany.; Institute of Neurogenetics, University of Lübeck, Lübeck, Germany., Ranjbar M; Laboratory for Angiogenesis and Ocular Cell Transplantation, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. eye.research101@gmail.com.; Department of Ophthalmology, University of Lübeck, Lübeck, Germany. eye.research101@gmail.com. |
| Abstrakt: |
To evaluate the significance of motion artifacts in optical coherence tomography angiography (OCTA) images of patients with Parkinson's disease (PD) and healthy controls. In this prospective, cross-sectional study subjects with medicated PD (ON) and healthy, age- and gender-matched volunteers were recruited. Participants underwent specific ophthalmological examinations, including OCTA. Angiograms of the superficial retinal capillary plexus were evaluated for the type and frequency of artifacts using a validated motion artifact score (MAS). A total of 30 PD patients (60 eyes), average disease duration of 9.61 ± 5.55 years, and 30 matched, healthy controls (60 eyes) were recruited. Twenty percent of all eyes had an eye disease, unknown to the participant, with a significant impact on OCTA results. After cleansing the dataset by excluding subjects with confounding ocular comorbidities 42 eyes of 28 PD patients and 53 eyes of 29 healthy controls were further evaluated. Overall MAS and all five subtypes of motion artifacts were comparable without significant differences between groups. OCTA can be used in treated PD patients (ON) without a significant increase in motion artifacts. Nevertheless, special attention should be paid to image quality during the acquisition of OCTA data, for which an experienced OCTA operator is useful. |
